Explore
Validate
LearnALX-803-341-C100
antibody from Enzo Life Sciences
Targeting: BIRC3
API2, c-IAP2, cIAP2, hiap-1, MALT2, MIHC, RNF49
Western blotAntibody data
- Antibody Data
- Antigen structure
- References [7]
- Comments [0]
- Validations [0]
Submit
Validation data
Reference
Comment
Report error
- Product number
- ALX-803-341-C100 - Provider product page
- Provider
- Enzo Life Sciences
- Proper citation
- Enzo Life Sciences Cat#ALX-803-341-C100, RRID:AB_11181487
- Product name
- c-IAP2 monoclonal antibody (human) (16E-6-3)
- Antibody type
- Monoclonal
- Antigen
- Recombinant protein fragment
- Description
- Protein G affinity purified.
- Reactivity
- Human
- Host
- Rat
- Isotype
- IgG
- Antibody clone number
- 16E-6-3
- Vial size
- 100 μg
- Storage
- -80°C
- Handling
- Avoid freeze/thaw cycles. After opening, prepare aliquots and store at -80¡C.
Submitted references Molecular determinants of Smac mimetic induced degradation of cIAP1 and cIAP2.
TAK1 is required for survival of mouse fibroblasts treated with TRAIL, and does so by NF-kappaB dependent induction of cFLIPL.
Cellular IAPs inhibit a cryptic CD95-induced cell death by limiting RIP1 kinase recruitment.
TRAF2 must bind to cellular inhibitors of apoptosis for tumor necrosis factor (tnf) to efficiently activate nf-{kappa}b and to prevent tnf-induced apoptosis.
TWEAK-FN14 signaling induces lysosomal degradation of a cIAP1-TRAF2 complex to sensitize tumor cells to TNFalpha.
IAP antagonists target cIAP1 to induce TNFalpha-dependent apoptosis.
Determination of cell survival by RING-mediated regulation of inhibitor of apoptosis (IAP) protein abundance.
Darding M, Feltham R, Tenev T, Bianchi K, Benetatos C, Silke J, Meier P
Cell death and differentiation 2011 Aug;18(8):1376-86
Cell death and differentiation 2011 Aug;18(8):1376-86
TAK1 is required for survival of mouse fibroblasts treated with TRAIL, and does so by NF-kappaB dependent induction of cFLIPL.
Lluis JM, Nachbur U, Cook WD, Gentle IE, Moujalled D, Moulin M, Wong WW, Khan N, Chau D, Callus BA, Vince JE, Silke J, Vaux DL
PloS one 2010 Jan 8;5(1):e8620
PloS one 2010 Jan 8;5(1):e8620
Cellular IAPs inhibit a cryptic CD95-induced cell death by limiting RIP1 kinase recruitment.
Geserick P, Hupe M, Moulin M, Wong WW, Feoktistova M, Kellert B, Gollnick H, Silke J, Leverkus M
The Journal of cell biology 2009 Dec 28;187(7):1037-54
The Journal of cell biology 2009 Dec 28;187(7):1037-54
TRAF2 must bind to cellular inhibitors of apoptosis for tumor necrosis factor (tnf) to efficiently activate nf-{kappa}b and to prevent tnf-induced apoptosis.
Vince JE, Pantaki D, Feltham R, Mace PD, Cordier SM, Schmukle AC, Davidson AJ, Callus BA, Wong WW, Gentle IE, Carter H, Lee EF, Walczak H, Day CL, Vaux DL, Silke J
The Journal of biological chemistry 2009 Dec 18;284(51):35906-15
The Journal of biological chemistry 2009 Dec 18;284(51):35906-15
TWEAK-FN14 signaling induces lysosomal degradation of a cIAP1-TRAF2 complex to sensitize tumor cells to TNFalpha.
Vince JE, Chau D, Callus B, Wong WW, Hawkins CJ, Schneider P, McKinlay M, Benetatos CA, Condon SM, Chunduru SK, Yeoh G, Brink R, Vaux DL, Silke J
The Journal of cell biology 2008 Jul 14;182(1):171-84
The Journal of cell biology 2008 Jul 14;182(1):171-84
IAP antagonists target cIAP1 to induce TNFalpha-dependent apoptosis.
Vince JE, Wong WW, Khan N, Feltham R, Chau D, Ahmed AU, Benetatos CA, Chunduru SK, Condon SM, McKinlay M, Brink R, Leverkus M, Tergaonkar V, Schneider P, Callus BA, Koentgen F, Vaux DL, Silke J
Cell 2007 Nov 16;131(4):682-93
Cell 2007 Nov 16;131(4):682-93
Determination of cell survival by RING-mediated regulation of inhibitor of apoptosis (IAP) protein abundance.
Silke J, Kratina T, Chu D, Ekert PG, Day CL, Pakusch M, Huang DC, Vaux DL
Proceedings of the National Academy of Sciences of the United States of America 2005 Nov 8;102(45):16182-7
Proceedings of the National Academy of Sciences of the United States of America 2005 Nov 8;102(45):16182-7
No comments: Submit comment
No validations: Submit validation data